Nektar Therapeutics NKTR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $55.63M-36.2% | $55.23M-43.9% | $62.6M-32.8% | $74.93M-19.6% | $87.25M-3.2% | ||
| —— | $55.23M-18.5% | $54.62M-13.5% | $62.52M+13.3% | $65.1M+18.5% | ||
| $122.53M-1.2% | $117.33M-3.0% | $116.36M-4.7% | $124.14M+11.7% | $123.98M+11.6% | ||
| $57.77M-28.6% | $68.67M-10.5% | $74.62M-3.0% | $77.51M-2.0% | $80.95M+5.8% | ||
| $190.25M-5.6% | $195.33M-4.1% | $160.69M-34.7% | $175.7M-31.6% | $201.55M-20.8% | ||
| -$134.62M— | -$140.1M— | —— | —— | —— | ||
| -242%— | -253.7%— | —— | —— | —— | ||
| -$17.59M-21.9% | -$15.39M-9.9% | -$15.69M-2.9% | -$15.05M-10.8% | -$14.43M-24.2% | ||
| -$152.21M-12.1% | -$155.49M-23.2% | -$120.79M+28.2% | -$122.81M+30.7% | -$135.73M+22.9% | ||
| —— | —— | -$428K-4,656% | -$386K-389% | -$152K+11.6% | ||
| -$158.1M-12.7% | -$164.08M-30.0% | -$128M+23.9% | -$129.53M+26.9% | -$140.3M+20.2% | ||
| -284.2%-123pp | -297.1%-169pp | -204.5%-23.8pp | -172.9%+17.2pp | -160.8%+34.2pp | ||
| -$8.23+32.0% | -$10.03-15.6% | -$10.51-53.9% | -$11.30-156% | -$12.11-1,216% | ||
| -$133.87M-6.7% | -$139.08M-20.8% | -$111.27M+24.5% | -$113.15M+28.0% | -$125.44M+20.2% | ||
| -240.6%-96.9pp | -251.8%-135pp | -177.7%-19.5pp | -151%+17.7pp | -143.8%+30.7pp | ||
| -$134.62M-4.6% | -$140.1M-17.2% | -$112.44M+26.5% | -$115.11M+29.6% | -$128.65M+21.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Nektar Therapeutics's revenue?
- Nektar Therapeutics (NKTR) generated $55.6M in revenue over the trailing twelve months, down 36.2% year over year.
- Is Nektar Therapeutics profitable?
- Nektar Therapeutics is not currently profitable: it reported a net loss of $158.1M over the trailing twelve months, a -284.2% net margin.
- What are Nektar Therapeutics's profit margins?
- Gross margin is 100.0% and operating margin is -242.0%, with a -284.2% net margin.
- What is Nektar Therapeutics's earnings per share?
- Nektar Therapeutics's diluted EPS over the trailing twelve months is $-8.23.
- Where does Nektar Therapeutics's income statement data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
